You just read:

New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

News provided by

AbbVie

Jun 12, 2019, 18:00 ET